The mission of the Survey Methods Core (SMC) facility is to assist Moffitt Cancer Center members with the design, implementation, and execution of research involving survey methods. Services provided by the SMC include consultations on research design, methods, and implementation, as well as the production and processing of scannable, web-based, and Computer Assisted Telephone Interviewing (CATI) surveys. Also offered are consultations about qualitative methods, including interviews, focus groups, and cognitive debriefing. The core has grown significantly since 2006. In addition to increasing and enhancing the range of services, the Core has added technical staff and expanded its physical space. The Core has more than doubled its space and now has four computer workstations in 300 square feet of space, as well as 300 square feet in a private CATI lab with four telephone interviewing stations. Currently there are three full-time positions and one part-time interviewer position. Since its inception, the SMC has implemented a working chargeback structure, increased its technical staff, and enhanced its menu of services. The Core's user base has been extended to include members from the Experimental Therapeutics and Molecular Oncology and Drug Discovery programs as well as those from the Health Outcomes and Behavior and Cancer Epidemiology. The Core requests CCSG Support of $83,457 which is 48% of its current operational budget. Over 84% of usage is by Moffitt members and peer-reviewed.
Survey methods are vital tools in cancer prevention, detection, and control research and are increasingly useful in clinical investigations of new cancer therapies. The data collection process, particularly for large-scale studies and studies using multiple sites, can be time consuming;however, services provided by the SMC have streamlined the process.
|Permuth, Jennifer B; Pirie, Ailith; Ann Chen, Y et al. (2016) Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. Hum Mol Genet 25:3600-3612|
|Weber, Jeffrey; Gibney, Geoffrey; Kudchadkar, Ragini et al. (2016) Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. Cancer Immunol Res 4:345-53|
|Reed, Damon R; Mascarenhas, Leo; Manning, Kathleen et al. (2016) Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies. Cancer Med 5:294-303|
|Turner, Joel G; Dawson, Jana L; Grant, Steven et al. (2016) Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. J Hematol Oncol 9:73|
|Haake, Scott M; Li, Jiannong; Bai, Yun et al. (2016) Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics. Clin Cancer Res :|
|Schabath, Matthew B; Massion, Pierre P; Thompson, Zachary J et al. (2016) Differences in Patient Outcomes of Prevalence, Interval, and Screen-Detected Lung Cancers in the CT Arm of the National Lung Screening Trial. PLoS One 11:e0159880|
|Kim, Jae-Young; Welsh, Eric A; Fang, Bin et al. (2016) Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer. Mol Cancer Res 14:1019-1029|
|Extermann, Martine; Leeuwenburgh, Christiaan; Samiian, Laila et al. (2016) Impact of chemotherapy on medium-term physical function and activity of older breast cancer survivors, and associated biomarkers. J Geriatr Oncol :|
|Jiang, Kun; Neill, Kevin; Cowden, Daniel et al. (2016) Expression of CAS/CSE1L, the Cellular Apoptosis Susceptibility Protein, Correlates With Neoplastic Progression in Barrett's Esophagus. Appl Immunohistochem Mol Morphol :|
|Sung, Hyeran; Kanchi, Krishna L; Wang, Xue et al. (2016) Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation. Oncotarget 7:23885-96|
Showing the most recent 10 out of 974 publications